Clinical trials: Major Depressive Disorder (MDD)
Major Depressive Disorder (MDD)
A Study in Patients With Major Depressive Disorder
This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).
- Trial name
- NCT03642964
- Testing
- CTC-501
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Chase Therapeutics Corporation
Major Depressive Disorder (MDD)
A Study of HS-10353 in Adult Participants With Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of continuous oral administration of HS-10353 in Chinese adults with depression.HS-10353 is a new generation of…
- Trial name
- NCT05938179
- Testing
- HS-10353 30mg oral capsules, HS-10353 50mg oral capsules
- Volunteers
- 144 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Major Depressive Disorder (MDD
Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
An open label, randomized, three-period, three-treatment, six-sequence, crossover, balanced, single dose, dose proportionality study.
- Trial name
- NCT05416762
- Testing
- Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
Major Depressive Disorder (MDD)
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
An open label, randomized, two-period, two-treatment [Treatment A (Investigational product administration under fasting condition) vs Treatment B (Investigational product administration under fed condition)], two-sequence…
- Trial name
- NCT05416957
- Testing
- Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
Major Depressive Disorder (MDD)
Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
An open label, randomized, three-period, three-treatment [Treatment A (test product administered without water), Treatment B (test product administered with water) and Treatment C (Reference product administered with water)]…
- Trial name
- NCT05417087
- Testing
- Vortioxetine Hemihydrobromide Orally Disintegrating Tablets, Vortioxetine Hydrobromide Tablets
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
Major Depressive Disorder (MDD)
The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.
- Trial name
- Ammoxetine (NCT05762458)
- Testing
- Ammoxetine
- Volunteers
- 240 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Major Depressive Disorder (MDD)
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.
- Trial name
- NCT05504486
- Testing
- Brexpiprazole
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD).
- Trial name
- NCT01123707
- Testing
- Aripiprazole, Escitalopram
- Volunteers
- 173 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111565
- Testing
- Escitalopram, Aripiprazole
- Where
- 53 sites in United States, Canada and 9 more
- Volunteers
- 137 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
The purpose of this study is to determine if LY03005 is effective and safe in improve MADRS score, as compared to placebo (no medicine) in participants with Major Depressive Disorder (MDD)
- Trial name
- NCT04853407
- Testing
- LY03005 extended-release tablet
- Where
- China
- Volunteers
- 558 people
- Sponsor
- Luye Pharma Group Ltd.
Major Depressive Disorder (MDD)
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.
- Trial name
- NCT05018013
- Testing
- Ammoxetine hydrochloride enteric-coated tablets, Duloxetine hydrochloride enteric-coated capsules
- Where
- China
- Volunteers
- 240 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111539
- Testing
- Escitalopram, Aripiprazole, Blinded capsule
- Where
- 62 sites in United States, Estonia and 7 more
- Volunteers
- 211 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
This study will assess efficacy, safety and tolerability of agomelatine (AGO178) 25 mg and 50 mg in patients with Major Depressive Disorder (MDD). This study includes an 8-week double-blind phase and a 52-week open-label phase.
- Trial name
- NCT00411242
- Testing
- agomelatine
- Where
- 51 sites in United States
- Volunteers
- 503 people
- Sponsor
- Novartis
Major Depressive Disorder (MDD)
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
The purpose of the study is to demonstrate that the efficacy and safety of deep brain rTMS, (Transcranial Magnetic Stimulation) H7-Coil treatment as add on treatment, is as good as the FDA cleared, H1-Coil, in subjects with major…
- Trial name
- NCT03012724
- Testing
- H7-Coil, H1-Coil
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- Brainsway
Major Depressive Disorder (MDD)
Scopolamine in Healthy Volunteers
This single-site clinical trial is an open-label study to identify the safety and pharmacokinetics of DPI-386 Nasal Gel (intranasal scopolamine gel) and IV Scopolamine.
- Trial name
- NCT03874130
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Major Depressive Disorder (MDD)
Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression
This feasibility study investigates effects of EEG-based low frequency, low emission magnetic cortical stimulation in comparison to a sham treatment in subjects with moderate to severe depressive disorder.
- Trial name
- NCT01683019
- Testing
- NeoSync EEG Synchronization Therapy
- Where
- 2 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Wave Neuroscience
Major Depressive Disorder (MDD)
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
The purpose of this study is to assess if LY2216684 (flexible dose of 12 to 18 milligrams [mg] or fixed dose of 6 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with Major Depressive…
- Trial name
- NCT01187407
- Testing
- LY2216684, SSRI
- Where
- 54 sites in United States, Croatia and 5 more
- Volunteers
- 1,480 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder (MDD)
European Drug Utilization Study
The purpose of this retrospective observational study is to evaluate the characteristics of patients receiving Seroquel XR as treatment for their Major Depressive Disorder.
- Trial name
- EUDUS (NCT01594996)
- Where
- Germany
- Volunteers
- 814 people
- Sponsor
- AstraZeneca